Session » Health Services Research Poster III – ACR/ARHP

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2171

A 5-Year National Trend in Acute Myocardial Infarctionamong Hospitalized Patients with Psoriatic Arthritis: Data from National Inpatient Sample

9:00AM-11:00AM: Abstract Number: 2183

Access to Prescription Drugs in Canada: Results from an Online Survey

9:00AM-11:00AM: Abstract Number: 2184

An Economic Evaluation on the Impact of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using Complement C4d Activation Products in a Multivariate Assay Panel (MAP)

9:00AM-11:00AM: Abstract Number: 2173

Budget Impact of Etanercept Versus Adalimumab for Treatment of Rheumatoid Arthritis in Biologic-Naïve Patients in the United Kingdom

9:00AM-11:00AM: Abstract Number: 2175

Change in Frequency of Arthroplasty Surgery in Rheumatoid Arthritis: A 13-Year Population Health Study

9:00AM-11:00AM: Abstract Number: 2182

Defining Alendronate Drug Holidays and Re-Initiation in US Medicare Data

9:00AM-11:00AM: Abstract Number: 2194

Develop a New Platform for Post-Marketing Vigilance Though Smart System of Disease Management (SSDM) Mobiles Tools: A Real World Cohort Study of RA Patients from China

9:00AM-11:00AM: Abstract Number: 2181

Development and Feasibility of a Web-Based Data Capture System to Collect Uniform Comprehensive Post-Total Knee Replacement Physical Therapy Intervention Data for Both Clinical and Research Purposes

9:00AM-11:00AM: Abstract Number: 2180

Differences in Longitudinal Disease Activity Measures between Research Cohort and Non-Cohort Participants with Rheumatoid Arthritis Using Electronic Health Record Data

9:00AM-11:00AM: Abstract Number: 2185

Direct Medical Costs for Medicare Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2190

Means of Collaboration between Ophthalmologists, Rheumatologists and Internists in the Management of Non-Infectious Uveitis: A Nationwide Study

9:00AM-11:00AM: Abstract Number: 2193

Online Direct-to-Patient Recruitment for Systemic Lupus Erythematosus Results in Rapid Enrollment

9:00AM-11:00AM: Abstract Number: 2172

Overuse of Glucocorticoids in Rheumatoid Arthritis: A National Survey of Primary Care Physicians

9:00AM-11:00AM: Abstract Number: 2179

Poor Rates of Screening for Retinal Toxicity in Patients on Antimalarial Medications: A Population-Based Study

9:00AM-11:00AM: Abstract Number: 2186

Process Evaluation of a Culturally-Sensitive, Community Based Self-Management Program for First Nations People with Arthritis and Their Families

9:00AM-11:00AM: Abstract Number: 2178

Provider Perceptions of Telerheumatology within the Veterans Health Administration: A National Survey Study

9:00AM-11:00AM: Abstract Number: 2188

Regional Analysis of Impact of Participation in a Patient Support Program on Clinical Outcomes Among Patients with Rheumatoid Arthritis Receiving Adalimumab (Humira)

9:00AM-11:00AM: Abstract Number: 2191

Safety of Ultrasound-Guided Injections Using Local Puncture Site Sterility

9:00AM-11:00AM: Abstract Number: 2174

Self-Report of Fracture History Compared to Fracture Codes from an Electronic Health Record Dataset

9:00AM-11:00AM: Abstract Number: 2187

Specialist Link Telephone Advice Cost Effectively Enhances Rheumatology Patient Care in Alberta, Canada

9:00AM-11:00AM: Abstract Number: 2176

The Association of Gout with Incident Giant Cell Arteritis in Older Adults

9:00AM-11:00AM: Abstract Number: 2189

Use of Smartphones in Collecting Patient Reported Outcomes (PROs): Feasibility of a Study Nested in a US National Cohort

9:00AM-11:00AM: Abstract Number: 2192

User Experience with Methotrexate in Managing Inflammatory Arthritis Under the Support of an Interprofessional Arthritis Care Team (UMTX Study)

9:00AM-11:00AM: Abstract Number: 2177

Workforce Requirements in Rheumatology: A Systematic Literature Reviewinforming the Development of a Workforce Prediction Risk of Bias Tool and the EULAR Points to Consider

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].